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• The when  how and what of microdosing,
• Technolocy behind (AMS and PET) and examples of 
microdosing studies.
• Validity of microdosing studies
• Perspectives for Controlled Release
• Conclusion
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Many scientific breakthroughs in biology !
How about new drugs ?
• Human genome projects
• Proteomics
• Metabollomics
Hi h Th h t i• g roug pu screen ng
• Improved in silico techniques. 
CT Caskey  Annu  Rev  Med  2007  58:1–16
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The Pharma challenge:-
Di Ph I Ph IIIPh IIP li i l Submission & scovery ase aseaserec n ca approv. 
• Overall time from discovery to approval of approx. 12 years
• Estimated cost for pharmaceutical development of $ 1 billion
• Patent protection only applies for 20-25 years. 
• Only 1 out of 5 to 1 out of 10 drugs reach the market
• Approximately 40% attrition due to unsuitable pharmacokinetics or 
metabolism
• Preclinical testing requires extensive and lengthy tox evaluations
A need for 21st century tools for 21st century pharmaceutical
19/07/2009CRS - 20094 Risø DTU, Technical University of Denmark
development (FDA, critical path document)
Microdosing could be one such tool !
Discovery Phase I Phase IIIPhase IIPreclinical Submission & approv. Phase 0
Phase 0
• Injection of drug compound in the 
microgram range  .
• Due to the low dose, no pharmacological
response expected and less animal testing for 
toxicology needed.
• Early acces to pharmacokinetics and 
pharmacodynamics
Bergström et al, Eur. J. Clin. Pharmacol, 2003, 357
Lappin et al  Nature Reviews in Drug Discovery  2003  233 
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Microdosing The industry perspective–
• Reduced time from PLC to Human administration
– Without microdosing, 12-18 months
– With microdosing, 4-8 months. 
• More compounds testet in humans
– Usually several preclinical leads
M t i i l d b t k t  li i k i  ll l  – os prom s ng ea s may e a en o c n c n para e .
• Potential to ”kill” unsuccessful PLC’s quickly and reduce overall costs. 
• Human pharmacokinetics and pharmacodynamics as basis for stop/go 
decisions. 
• Additional cost reductions due to reduced Tox-packages and reduced
requirements to drug products amounts and quality. 
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The Regulators Perspective
• Potential as an important tool in speeding up drug development process
and reduce costs. 
• Critical to ensure test subject safety
• Potential in reducing the use of test animals for safety and tox studies. 
• EMEA white paper, 2004. ”Position paper on non-clinical safety studies to 
support clinical trials with a single microdose”
• FDA guidance for industry, eIND in 2006. ”Guidance for Industry, 
Investigators and Reviewers, Exploratory IND studies”. 
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Regulations for microdose studies
• Small amounts of drug product administered: 
– 1/100th of the dose calculated to give a pharmacological response. 
– Maximum 100 µg
Maximum 30 nmoles for protein products (FDA )–
• Extended single dose studies to asses toxicology
O  li i  h j tifi d– ne mamma en spec es w en us e
– Study should establish a dose inducing a minimal toxic effect. 
– Alternatively, for drugs with low toxicity, a safety margin of 100 and 
1000 is required by FDA and EMEA respectively  .
• Genotoxicity studies
EMEA i t t f  t i it– requ res es or geno ox c y
– FDA requires no routine genetic toxicology test
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But  are genotoxicity studies necesarry ??,
• EMEA/CHMP/SWP/5199/02
– For”Safe” chemical structures,- impurities < 1,5 µg/day may be discarded for 
genotoxicity (Treshold for toxocological concern (TTC))
– For structures with genotoxic structures, impurities <0.15 µg/day may used as 
TTC
– For products with short term administration, TTC could be higher. 
• PhRMA white paper
– Agrees with TTC of 1.5 µ/day
– Suggest a limit of 120 µg/day for short interval administration. 
• For PET examinations, genotoxic potential of radiation 10-100 times higher than
that of the administered chemical. 
Suggested that for microdosing studies  genotoxicity studies not obligatory  • , .
H Lundquist, G Antoni, B Långstrøm, Eur J Clin Pharmacol. (2007), 641
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But  to study the fate of < 100 µg you need, –
to use the large binocular !!
• 40 femtomol/ml if evenly
distributed in blood (5 l)
• 2.9 femtomol/ml if
evenly distributed in body
fluid (70 l)
You need femto – atto molar
sensitivity
• Accelerator Mass Spectroscopy (AMS)
• Positron Emission Tomography (PET)
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The AMS study
• Requires GMP (or GLP) 
manufacture of 14C-labelled 
drug product. 
T i ll i t i j ti f • yp ca y n ravenous n ec on o
drug product as well as intended
route of administration. 
• Typically less than 50 nCi 14C-
drug administered (1.85 kBq)
• Drawing of blood samples  urine,
etc. for AMS sampling. 
• After sample preparation and 
compound separation, collected
samples are subjected to AMS
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An example of an AMS study
• α1A-Adrenoceptor antagonist
• Injection of 50 nCi C 14 labelled Drug -
product (5 µg, 50 µg and 500 µg)
• Collection of blood samples (>100 h) and 
urine samples (72 h)
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G. Lappin, RC Garner, Nature Reviews in Drug Discovery, 2003, 233
The PET approach
Clinical sites: 
Usually hospital based
with PET(/CT)
Should have in-house blood
analysis capabilities. 
Highly specialised staff (medicine, 
physics  chemistry) ,
Manufacturing sites: 
GMP or GMP-like production
18F- og 11C tracers with high
specific activity.
Highly specialised staff (Physics, 
chemistry and pharmacy) 
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Example of a PET study 18F Ciprofloxacin–
700 MBq
0-30 min Post injection
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M Brunner et al, Antimicrob Agents Chemother, 2004, 3850
18F Ciprofloxacin cont- .
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M Brunner et al, Antimicrob Agents Chemother, 2004, 3850
But ! Is microdosing truly representative ?
• Is scaling from microdoses to therapeutic doses linear ?
• Nonlinearity could be induced by saturations of: 
– binding to target
– Affinity to other systems
– Metabolism
– Elimination pathways. 
• If not scaleable  high risks of misinterpretations, .
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Recent studies confirm an approximate linearity
• CREAM study (Consortium for Resourcing and Evaluating AMS Microdosing)
– Five drugs known for difficult human PK prediction studied
– Dosing at microdose and therapeutic dose levels
Approximately 70% correspondance  – .
• EUMAPP (European Microdosing AMS Partnership Programme)
S d  ith bl ti di ti d l  f  PK– even rugs w pro ema c pre c ve mo e s or
– Assesment of pharmacokinetic linearity from micro- to therapeutic dose
– For all drugs, IV microdoses predicted t½, CL and V very well. 
O l d d d l ll b ld b l d f h l– ra  ata i  not sca e as we ut cou e exp aine rom c emica
and metabolic properties.  
CREAM: RC Garner, Drug Discovery Today, 2005, 449
EUMAPP: http://www.eumapp.com/
19/07/2009CRS - 200917 Risø DTU, Technical University of Denmark
AMS & PET approach – which is the better ?
B th ill id i iti l h ki ti d t  d l bli th  ti ti f • o w prov e n a p armaco ne c a a an va ues ena ng e es ma on o
t½, clearance (CL) and distribution volumes (V).
• Both have shown to give data from microdosing that are representative for the 
therapeutic dose levels (within a factor of 2)
• Both provide an oppertunity to obtain early data to support decision making in 
preclinical and early clinical trials. 
• AMS gives the oppertunity of investigating drugs with long biological half-lives.
• AMS is less expensive and generally faster to set up
• PET gives the oppertunity of additional tissue distributions and kinetics. PET 
therefore provides early indications of pharmacodynamic properties. 
It depends on your question – they compliment each other
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Microdosing and Controlled release –
Perspectives from an outsider !
CR is about the delivery more than about the active compound. 
Potential for microdosing in the investigation of CR effects
Sustained release
Bioavailability
Prodrugs
Great potential for microdosing and PET imaging for investigation of 
targeting effects. 
Targeting of API with carrier – does it deliver
ADME information for API/Carrier
(Receptor binding studies/occupancy)
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But – will your carrier/formulation etc. be MICRO ??
In Conclusion
Mi d i i   l bl t l i  th  l h f cro os ng s a va ua e oo n e very ear y p ases o
clinical development. 
The approach is accepted by authorities and adequate
i tifi f h  b id d  sc en c proo as een prov e .
AMS and PET are both valuable tools in microdosing. Which to 
use depends on the question asked as the compliment each
th  o er.
Microdosing with PET or AMS has potential also in the 
investigation of controlled release investigations. 
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